Sartorius is investing €100 million (US$113 million) between 2021 and 2025 to expand capacities for production, innovation, and storage at its French facilities in Aubagne, Cergy, and Lourdes.
Sartorius announced on Nov. 26, 2021 that it plans to invest a total of €100 million (US$113 million) between 2021 and 2025 to expand and upgrade its Aubagne, Cergy, and Lourdes facilities in France. The expansions will include:
The investment will enable Sartorius to further boost performance, increase its innovation, and meet growing market demand. Under its growth strategy, Sartorius will create up to 400 new permanent employment positions at the four French sites between 2021 and 2025. The company is seeking new talent in operations, such as production managers, machine operators, continuous improvement managers; product development staff, including engineers, data analysts; and marketing personnel. Sartorius will also support its teams by facilitating the acquisition of new, cutting-edge skills, particularly in automation and digitalization of equipment used in workflows.
“We see our biopharmaceutical customers entering a new phase characterized by a high pace of innovation, substantial investments in their operations, and increasing demands on us as their suppliers. We are supporting their efforts, significantly adding capacity and increasing the speed of delivery,” said Luc Burgard, managing director of Sartorius Stedim FMT and head of operations of the Bioprocess Solutions Division at Sartorius, in a company press release. “The investments in our French facilities will strengthen our industrial capabilities in this country and secure the long-term future of our operations here.”
Source: Sartorius
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.